. 2018 Jul 2;10:1807–1816. doi: 10.2147/CMAR.S168515

Table 2.

Stratification analysis of risk genotypes with neuroblastoma susceptibility

Variables	rs57961569 (cases/controls)		AOR (95% CI)	P-value^a	rs9653226 (cases/controls)		AOR (95% CI)	P-value^a	Combined		AOR (95% CI)	P-value^a
Variables	GA	GG	AOR (95% CI)	P-value^a	TT/TC	CC	AOR (95% CI)	P-value^a	0–1	2–3	AOR (95% CI)	P-value^a
Age, month
≤18	59/156	67/149	1.19 (0.78–1.80)	0.419	112/274	34/66	1.25 (0.78–2.00)	0.347	80/200	66/140	1.18 (0.80–1.74)	0.408
>18	112/256	135/223	1.38 (1.01–1.88)	0.040	228/458	55/86	1.29 (0.88–1.87)	0.189	156/335	127/209	1.31 (0.98–1.75)	0.073
Gender
Female	72/181	86/156	1.38 (0.94–2.02)	0.098	136/308	49/68	1.63 (1.07–2.48)	0.023	102/230	83/146	1.28 (0.90–1.83)	0.172
Male	99/231	116/216	1.24 (0.90–1.73)	0.190	204/424	40/84	0.99 (0.66–1.50)	0.971	134/305	110/203	1.23 (0.90–1.68)	0.189
Sites of origin
Adrenal gland	53/412	89/372	1.88 (1.30–2.72)	0.0008	120/732	44/152	1.79 (1.21–2.64)	0.003	79/535	85/349	1.66 (1.18–2.32)	0.003
Retroperitoneal	44/412	41/372	1.02 (0.65–1.60)	0.936	76/732	20/152	1.27 (0.76–2.15)	0.365	56/535	40/349	1.09 (0.71–1.67)	0.706
Mediastinum	49/412	55/372	1.25 (0.83–1.89)	0.281	105/732	18/152	0.82 (0.48–1.39)	0.455	70/535	53/349	1.17 (0.80–1.71)	0.423
Others	23/412	11/372	0.53 (0.25–1.10)	0.086	34/732	4/152	0.57 (0.20–1.62)	0.291	29/535	9/349	0.48 (0.22–1.02)	0.055
Clinical stages
I + II + 4s	76/412	83/372	1.22 (0.87–1.71)	0.260	152/732	27/152	0.84 (0.54–1.32)	0.453	101/535	78/349	1.19 (0.86–1.65)	0.292
III + IV	88/412	110/372	1.40 (1.02–1.92)	0.037	170/732	57/152	1.63 (1.15–2.31)	0.006	121/535	106/349	1.35 (1.004–1.81)	0.047

Notes:

Adjusted for age and gender. Bold figures indicate 95% CI excluded 1 or P<0.05.

Abbreviations: AOR, adjusted odds ratio; CI, confidence interval.